As a physician, wouldn't you consider the desires of your patients? Afrezza has been in the market for over a year and a half now and yet not a single complaint about lung toxicity. In fact, anyone that has used the product raves about it, ultra fast acting and "blows" away any injectable mealtime insulin. Sanofi blew it and they know it. They did not try and even commercialize the product, so they sandbagged, trying to protect their turf. Not only that, they threw away money at it hoping it either go away or if it stuck, they would simply reap the benefits. (this is what they are doing with their 30 launches a year, see what sticks)
Toujeo is simply their attempt to further protect their turf. Sanofi is not an innovative company, sort of an
un-wielding, bureaucratic bloated organization. For shame they let Afrezza slip away. This will come and bite them in the rear end.
Agreed. very good. Now if only Mannkind can capitalize on this, we may be talking about a blockbuster beyond anyone's wildest dreams. Send this over to Matt!
ha funny. Sanofi sandbagged MNKD's product. they have what is called Toejoe, not even close to the gift horse they had. The only reason they sandbagged it is because they were scared it would eat at their lantus franchise. They purposely partnered so as to bury inhaled insulin. They are a bloated dysfunctional company. Their CEO is what you call a bandaid, but the hemorrhaging hasn't stopped. see you at $20